Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hematological Malignancy, Advanced Breast Cancer
- Main trialPhase 1/2
- “This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.”In the company’s words, NCT07873827 on ClinicalTrials.gov
Other drugs for Hematological Malignancy
- Givinostat HydrochlorideItalfarmaco · Phase 3
- QTX-2101Quetzal Therapeutics · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- PelabresibNovartis · Phase 3
Coming up2
- 24 Oct 2027Phase 1 trial completes · ClinicalTrials.gov
- 12 May 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 12 May 2028 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | |
| Phase 1Recruiting | 24 Oct 2027 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026